Supernus Pharmaceuticals (SUPN) Retained Earnings (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Retained Earnings data on file, last reported at -$255000.0 in Q1 2026.

• On a quarterly basis, Retained Earnings fell 100.05% year-over-year to -$255000.0 in Q1 2026; TTM through Mar 2026 was -$255000.0, a 100.05% decrease from a year earlier, with the FY2025 full-year figure at $517.9 million, up 8.02% from the prior year.
• Retained Earnings for Q1 2026 stood at -$255000.0, down from $517.9 million in the prior quarter.
• Over the last five years, Retained Earnings for SUPN reached as high as $544.6 million in Q1 2025 and fell as low as -$1.8 million in Q2 2023.
• Historically, Retained Earnings has averaged $419.1 million across 5 years, with a median of $454.0 million in 2022.
• Across the five-year window, Retained Earnings plunged 100.39% in 2023 and surged 28415.55% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $481.2 million in 2022, then decreased by 8.68% to $439.5 million in 2023, then advanced by 9.09% to $479.4 million in 2024, then increased by 8.02% to $517.9 million in 2025, then plunged by 100.05% to -$255000.0 in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$255000.0 in Q1 2026, $517.9 million in Q4 2025, and $527.7 million in Q3 2025.